United Therapeutics (UTHR) is confident that about higher patient demand for its oral drug, Orenitram.
The company expects demand for Orenitram to rise due to research findings and gradual label expansion due to four ongoing research programs. These programs are expected to contribute to Orenitram’s revenue growth for the next five years.
These developments should boost United Therapeutics’ stock as well as the SPDR S&P MIDCAP 400 ETF (MDY). United Therapeutics makes up about 0.37% of MDY’s total portfolio.
New research programs
Orenitram was approved for Group 1 PAH patients in December 2013, based on positive results from FREEDOM-M trial. To further boost the drug’s sales, United Therapeutics is conducting a Phase IV FREEDOM-EV trial. The study aims to establish Orenitram’s efficacy in improving morbidity and mortality rates in Group 1 PAH patients who are already using another oral PAH therapy. If Orenitram’s superior clinical profile is proved, United Therapeutics plans to rebrand the drug as OreniPlus.
In another clinical study, Orenitram is expected to demonstrate higher benefit than Tadalafil and Ambrisentan in Group 1 PAH patients. Orenitram is also being explored for Group 2 and Group 5 PAH patients in SOUTHPAW and IRON studies, respectively. To learn more about efforts to safeguard Orenitram’s market share, see Understanding the Sales Potential of United Therapeutics’ Orenitram.
In the next part of this series, we’ll analyze United Therapeutics’ research pipeline in greater detail.